{
    "root": "d7253a99-928d-4f20-aa67-786837f19411",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Carisoprodol",
    "value": "20250203",
    "ingredients": [
        {
            "name": "CARISOPRODOL",
            "code": "21925K482H"
        },
        {
            "name": "HYPROMELLOSE 2910 (50 MPA.S)",
            "code": "1IVH67816N"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        }
    ],
    "indications": "carisoprodol indicated relief discomfort associated acute , painful musculoskeletal conditions adults . limitation carisoprodol used short periods ( two three weeks ) adequate evidence effectiveness prolonged established acute , painful musculoskeletal conditions generally short duration . [ ( 2 ) ] .",
    "contraindications": "recommended dose carisoprodol 350 mg three times day bedtime.the recommended maximum duration carisoprodol two three weeks .",
    "warningsAndPrecautions": "350 mg tablets : round , convex , white tablets , inscribed 111 one side \u201c \u201d side . ndc 71335-9621-1 : 14 tablets bottle ndc 71335-9621-2 : 28 tablets bottle ndc 71335-9621-3 : 60 tablets bottle ndc 71335-9621-4 : 20 tablets bottle ndc 71335-9621-5 : 30 tablets bottle ndc 71335-9621-6 : 84 tablets bottle ndc 71335-9621-7 : 90 tablets bottle ndc 71335-9621-8 : 100 tablets bottle ndc 71335-9621-9 : 120 tablets bottle ndc 71335-9621-0 : 56 tablets bottle storagestore controlled room temperature 20\u00b0 - 25\u00b0c ( 68\u00b0 - 77\u00b0f ) . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "carisoprodol contraindicated patients history acute intermittent porphyria hypersensitivity reaction carbamate meprobamate .",
    "indications_original": "Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults.\n                  \n                     Limitation of Use\n                     Carisoprodol should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [see \n                     \n                        Dosage and Administration (2)\n                     ].",
    "contraindications_original": "The recommended dose of carisoprodol is 350 mg three times a day and at bedtime.The recommended maximum duration of carisoprodol use is up to two or three weeks.",
    "warningsAndPrecautions_original": "350 mg Tablets: round, convex, white tablets, inscribed with 111 on one side and \u201cO\u201d on the other side.\n                  \n                     NDC 71335-9621-1: 14 Tablets in a BOTTLE\n                     NDC 71335-9621-2: 28 Tablets in a BOTTLE\n                     NDC 71335-9621-3: 60 Tablets in a BOTTLE\n                     NDC 71335-9621-4: 20 Tablets in a BOTTLE\n                     NDC 71335-9621-5: 30 Tablets in a BOTTLE\n                     NDC 71335-9621-6: 84 Tablets in a BOTTLE\n                     NDC 71335-9621-7: 90 Tablets in a BOTTLE\n                     NDC 71335-9621-8: 100 Tablets in a BOTTLE\n                     NDC 71335-9621-9: 120 Tablets in a BOTTLE\n                     NDC 71335-9621-0: 56 Tablets in a BOTTLE\n                  \n                  StorageStore at controlled room temperature 20\u00b0 - 25\u00b0C (68\u00b0 - 77\u00b0F).\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Carisoprodol is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate."
}